Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke

Translational Stroke Research

Volumn 3, Issue 2, 2012, Pages 286-295

  Simard, J Marc ^a   Woo, Seung Kyoon ^a   Tsymbalyuk, Natalia ^a   Voloshyn, Oksana ^a   Yurovsky, Vladimir ^a   Ivanova, Svetlana ^a   Lee, Ryan ^a   Gerzanich, Volodymyr ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral ischemia; Glibenclamide; Rat; Recombinant tissue plasminogen activator; Stroke; Sur1

Indexed keywords

ALTEPLASE; GLIBENCLAMIDE; SULFONYLUREA RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECANALIZATION; STROKE;

EID: 84861664143     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0149-x     Document Type: Article

References (33)

1. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992; 32: 78-86.
2. del Zoppo GJ, Saver JL, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40: 2945-8.
3. Erdey-Gruz T. Transport phenomena in electrolyte solutions. London: Adam Higler; 1974.
4. Fagan SC, Nagaraja TN, Fenstermacher JD, et al. Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model. Neurol Res. 2003; 25: 377-82.
5. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009; 40: 2244-50.
6. Furlan AJ. Clot retrieval for stroke should be restricted to clinical trials: no. Stroke. 2010; 41: 194-5.
7. Gerzanich V, Ivanov A, Ivanova S, et al. Alternative splicing of cGMP-dependent protein kinase I in angiotensin-hypertension: novel mechanism for nitrate tolerance in vascular smooth muscle. Circ Res. 2003; 93: 805-12.
8. Gianotto EA, Arantes RP, Lara-Filho MJ, et al. Dissolution test for glibenclamide tablets. Quim Nova. 2007; 30: 1218-21.
9. Haelewyn B, Risso JJ, Abraini JH. Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats? J Cereb Blood Flow Metab. 2010; 30: 900-3.
10. Khan M, Elango C, Ansari MA, et al. Caffeic acid phenethyl ester reduces neurovascular inflammation and protects rat brain following transient focal cerebral ischemia. J Neurochem. 2007; 102: 365-77.
11. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981; 46: 561-5.
12. Kornyshev AA, Kuznetsov AM, Spohr E, et al. Kinetics of proton transport in water. J Phys Chem B. 2003; 107: 3351-66.
13. Kotwica Z, Hardemark HG, Persson L. Intracranial pressure changes following middle cerebral artery occlusion in rats. Res Exp Med (Berl). 1991; 191: 99-104.
14. Murata Y, Rosell A, Scannevin RH, et al. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008; 39: 3372-7.
15. Nistico R, Piccirilli S, Sebastianelli L, et al. The blockade of K(+)-ATP channels has neuroprotective effects in an in vitro model of brain ischemia. Int Rev Neurobiol. 2007; 82: 383-95.
16. Okubo S, Igarashi H, Yamaguchi H, et al. Therapeutic time window of rt-PA on embolic stroke in rat. Int Congr Series. 2003; 1252: 203-7.
17. Overgaard K, Meden P. Influence of different fixation procedures on the quantification of infarction and oedema in a rat model of stroke. Neuropathol Appl Neurobiol. 2000; 26: 243-50.
18. Sayeed I, Wali B, Ishrat F, et al. Glybenclamide administration attenuates infarct volume, hemispheric swelling and functional deficits following permanent focal cerebral ischemia in rats. Society of Neuroscience Meeting, Washington DC. 2011; Poster # 62. 05/FF11.
19. Shimamura N, Matchett G, Tsubokawa T, et al. Comparison of silicon-coated nylon suture to plain nylon suture in the rat middle cerebral artery occlusion model. J Neurosci Meth. 2006; 156: 161-5.
20. Silasi G, MacLellan CL, Colbourne F. Use of telemetry blood pressure transmitters to measure intracranial pressure (ICP) in freely moving rats. Curr Neurovasc Res. 2009; 6: 62-9.
21. Simard JM, Chen M, Tarasov KV, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med. 2006; 12: 433-40.
22. Simard JM, Geng Z, Woo SK, et al. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2009; 29: 317-30.
23. Simard JM, Tsymbalyuk N, Tsymbalyuk O, et al. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke. 2010; 41: 531-7.
24. Simard JM, Tsymbalyuk O, Ivanov A, et al. Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. J Clin Invest. 2007; 117: 2105-13.
25. Simard JM, Yurovsky V, Tsymbalyuk N, et al. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke. 2009; 40: 604-9.
26. von Kummer R, Holle R, Rosin L, et al. Does arterial recanalization improve outcome in carotid territory stroke? Stroke. 1995; 26: 581-7.
27. Wang C, Liu JL, Sang HF, et al. Therapeutic time window of flurbiprofen axetil's neuroprotective effect in a rat model of transient focal cerebral ischemia. Chin Med J (Engl). 2008; 121: 2572-7.
28. Williams AJ, Berti R, Dave JR, et al. Delayed treatment of ischemia/reperfusion brain injury: extended therapeutic window with the proteosome inhibitor MLN519. Stroke. 2004; 35: 1186-91.
29. Williams AJ, Myers TM, Cohn SI, et al. Recovery from ischemic brain injury in the rat following a 10 h delayed injection with MLN519. Pharmacol Biochem Behav. 2005; 81: 182-9.
30. Woo SK, Kwon MS, Geng Z, et al. Sequential activation of hypoxia-inducible factor 1 and specificity protein 1 is required for hypoxia-induced transcriptional stimulation of Abcc8. J Cerebr Blood Flow Metabol. 2011.
31. Yanamoto H, Nagata I, Niitsu Y, et al. Evaluation of MCAO stroke models in normotensive rats: standardized neocortical infarction by the 3VO technique. Exp Neurol. 2003; 182: 261-74.
32. Yu YM, Kim JB, Lee KW, et al. Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke. 2005; 36: 2238-43.
33. Zhang L, Zhang ZG, Zhang R, et al. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke. Circulation. 2003; 107: 2837-43.